19th Oct 2023 19:39
Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.
Current stock price: 2.05 pence, up 15% in London on Thursday
12-month change: down 61%
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
EVG.L